Author: BioactiveCompoundLibrary

Relevant to neuronal activity, AMPKmediated changes in long-term potentiation are mTOR-dependent. Differences in acute seizure test profiles between three different treatments that affect AMPK activity support the hypothesis that downstream effects of neuronal mTOR inhibition likely depend on additional factors specific to each intervention. Rapamycin is known to bind FKBP12 to specifically inhibit mTORC1activity. Evidence that rapamycin acts similarly in vivo is shown by the ability of rapamycin and its derivatives to decrease recurrent seizures in animals and patients where TORC1 activity is abnormally high. Thus, it generally is LY294002 154447-36-6 assumed that rapamycin exerts its antiseizure actions by decreasing TORC1 activity. Protection in drug-induced chronic seizure models raises the possibility that mTOR inhibitors reverse a seizureinduced increase in the mTOR pathway. Specifically, after kainic acid-induced status epilepticus, increases in mTOR activity are noted 1-6 h after seizure onset, then decrease to baseline values, only to increase again 3 days after onset. Both of these increases are reversed by administration of rapamycin. However, the connection between mTOR activity and excessive neuronal activity during seizures is not clear. mTOR activity is required in dendrites for arbor and spine morphogenesis in some studies, raising the possibility that these changes in neuronal morphology may impact seizures and/or epilepsy. Rapamycin also inhibits mossy fiber sprouting in a Fingolimod number of models of status epilepticus. However, the importance of inhibiting mossy fiber sprouting is unclear because rapamycin can prevent mossy fiber sprouting without protecting against seizures after pilocarpine-induced status epilepticus. Electrophysiologically, mTOR is necessary for long-term potentiation and long-term depression.The effect of rapamycin on synaptic transmission may be mediated via decreased neuronal excitability and/or neurotransmitter release. Whether these morphological and physiological effects are the specific mechanism of seizure protection is unclear. In summary, decreased rapamycin-related neuronal excitability in some paradigms may be the result of mTOR inhibition but these studies do not rule out the possibility of an “off-target” effect, particularly given the broad effects of mTOR activity on protein synthesis, lipid metabolism, and autophagy. The limited seizure protection after a 3 d rapamycin exposure in the seizure-na? ��ve mice studied here may be due to unintended deleterious effects of prolonged mTOR suppression, in contrast to physiological mTOR suppressors where mTOR activity eventually rebounds. Another potential explanation is that the 3 d rapamycin regimen used here may suppress activity of the other mTOR protein complex, TORC2, with a subsequent deleterious effect on Akt activity. Consistent with only transient protection in the MES-T test, there may be an optimal degree of timing or extent of mTOR suppression that confers seizure protection in preclinical tests, though it is conceivably difficult to pharmacologically achieve such a balance. Finally, rapamycin is unlikely to have global antiseizure benefits, as it fails to protect in a model of infantile spasms induced by betamethasone and NMDA, even when administered before and after spasms started. Pretreatment or sustained exposure to rapamycin appears to be necessary to prevent seizures in preclinical models, as outlined previously. A requirement for prolonged rapamycin treatment is consistent with our finding that a 3-day treatment with rapamycin is more effective than a short 6 h treatment prior to kainic acid-induced seizures.

On the basis of their selectivity for PKCs and CAMKs, we chose to primarily focus on the 4-azaindole series of inhibitors, since they clearly displayed greater selectivity for PKD1 than the quinolinylmethylenethiazolinone derivative. 4-Azaindoles have previously been developed and characterized as inhibitors of p38a/b by Trejo et al.. Compounds 140 and 139 have been designed to reduce the oxidation at the 4-pyridyl nitrogen, a predominant site of metabolic oxidation. As a result of this modification, in vivo efficacy has been demonstrated for compounds 140 and 139 in an acute rat model of LPS-stimulated TNFa synthesis, providing favorable pharmacokinetic parameters for compound 140. Based on the desirable drug-like physical properties and promising PK/PD values, compound 140, and most likely 139, were deemed potent and selective orally available p38 inhibitors. These findings provide strong support for further development of the 140 and 139 series of analogs as drug/lead structures towards potent and selective PKD1 inhibitors, or dual PKD1/p38 inhibitors, with in vivo activity. Although a kinase profile reveals a few additional targets of 4-azaindoles, compound 140 in general displayed excellent selectivity as compared to the non-substituted 4,7-azaindoles, indicating there remains a distinct possibility to achieve greater selectivity Pazopanib through further medicinal chemistry modifications. On the other hand, although it is desirable to obtain sole selectivity for a single kinase, multitargeted protein kinase inhibitors tailored towards a small subset of kinases with distinct biological functions could be more attrY-27632 ROCK inhibitor active therapeutically; and, in fact, this strategy has proven to be an effective treatment in oncology. In this regard, PKD inhibitors with dual action on p38a might be equally attractive therapeutically, since both kinases have been implicated in inflammatory responses and cancer development. To further explore the mechanism of actions of these active PKD1 compounds, molecular modeling technologies were utilized to investigate putative binding modes. The threedimensional structure of PKD1 was built based on high-resolution crystal structures of homologues, and the catalytic domain, which consists of two lobes and an intervening linker, was well modeled. Subsequently, docking simulations were carried out, in which all ligands were docked into the putative ATP binding pocket of the kinase domain, and the resulting docking scores were relatively high. The interactions between the active lead compound 139 and the PKD1 kinase domain were further illustrated in detail. The modeling results are congruent with our experimental findings, demonstrating that these compounds are PKD1 inhibitors binding to the ATP site of kinase domain. The computational analyses provide additional insights into the possible molecular interactions and important binding residues of PKD1 and will prove useful in our future pharmacophore refinements. Influenza is one of the most common infectious diseases, affecting millions of people around the world every year. Occasionally, it causes a catastrophic pandemic such as the “Spanish flu” in 1918, which killed 30-50 million people worldwide. The most effective means of protection against influenza is vaccination; however, its effectiveness has been limited because etiological influenza A and B viruses constantly undergo antigenetic change. Moreover, the time needed to prepare a vaccine against a newly isolated influenza virus is more than half a year. This makes an emergency vaccine preparation against a pandemic influenza virus, such as the 2009 pandemic, difficult. However, as a vaccine alternative, several anti-influenza drugs have been developed.

Recently, selective inhibitors for CDK4 have gained substantial interest. For example the orally active small molecule PD0332991, which induces G1 arrest in primary myeloma cells, prevents tumor growth by specific inhibition of CDK4/6 and is now in Phase 2 clinical trials. The natural compound fascaplysin, originally isolated from the sponge Fascaplysinopsis Bergquist, is a kinase inhibitor with enticing selectivity for CDK4 relative to the close homolog CDK2, and also shows approximately eightfold selectivity over CDK6. Approximating the dissociation constant KD with IC50 and using the relation DG0 =2RTlnKD, the difference in the free energy of binding between the CDK4/fascaplysin and CDK2/fascaplysin complexes can be calculated to 4.2 kcal/mol. Considering the close structural similarity of the active sites of CDK2, CDK4 and CDK6, and the relatively small size and rigid structure of fascaplysin, the observed selectivity is remarkable. Chemically, fascaplysin is a planar, aromatic compound with no freely rotatable single bonds. It comprises five condensed rings, the central ring includes a positively charged imminium nitrogen. An indol-NH and a carbonyl can act as H-bond donor and H-bond acceptor, respectively. The H-bond donor and H-bond acceptor in fascaplysin are oriented in parallel spaced at,2.6 A ?, a feature shared with other kinase inhibitors. The fascaplysin framework has been used to synthesise a series of selective CDK4 inhibitors, though in most cases selectivity was partially lost in the redesign process. So what are the features that could explain the remarkable selectivity of fascaplysin? There is a considerable amount of structural information on CDKs available to help addressing this question. More than 100 CDK2 structures in complex with small molecules are deposited in the protein databank. However, compared to CDK2, structural information on CDK6 and CDK4 with inhibitors bound is scarce, in fact the first CDK4 structures have only been published recently. In this work, we have studied this example of charge-determined protein-ligand interactions using a variety of methods from the molecular modelling and drug design fields. The binding of inhibitors to protein receptors with high affinity and specificity is central to structure-based drug design applications. The quest for the calculation of binding affinities remains one of the main goals of modern computational biophysical methods. The most accurate methods for calculating binding free energies are based on molecular dynamics simulations which predict the physical properties of the protein-ligand complexes based on atomistic structural models. The energetic consequences of small structural Staurosporine 62996-74-1 changes in inhibitor complexes have been successfully studied using thermodynamic integration. An added benefit of TI calculations, as compared to empirical ligand Sorafenib Raf inhibitor docking algorithms is that the former include accurate estimates of binding entropy as well as enthalpy, based on rigorous statistical thermodynamics. In this work, we specifically address the contribution of the positive charge of fascaplysin to selectivity by applying thermodynamic integration calculations. In silico, fascaplysin can be modified easily by the iso-electronic substitution of the positively charged nitrogen to a charge neutral carbon atom, resulting in a compound, which for clarity and simplicity we refer to as carbofascaplysin. By calculating the energetic effect of this substitution for the protein-inhibitor complexes of both CDK2 and CDK4, we can quantify the impact of the positive charge of fascaplysin on its specificities towards CDK2 and CDK4.

In white adipocytes, the lipid ester core consists almost exclusively of triglycerides, whereas in many non-adipocytes LDs contain both TG and cholesterol esters in various ratios. TG synthesis is facilitated in the presence of excess fatty acids. In many non-adipocytes in culture, only a small number of LDs exist under normal conditions, but the addition of unsaturated fatty acids such as oleic acid to the medium induces abundant TG-rich LDs. CE metabolism has been studied most actively using macrophage foam cells, which take up significant quantities of plasma lipoproteins; in contrast, the general conditions that induce CE accumulation in other cell types are not well known. Degradation mechanisms have also been more thoroughly analyzed for TG than for CE. The regulatory mechanism of cytosolic lipases, including adipocyte triglyceride lipase and hormone-sensitive lipase, has been rapidly unveiled. In contrast, the enzymes engaged in CE hydrolysis have not been firmly established, even in macrophage foam cells. A recent study revealed that autophagy is involved in the degradation of LDs in hepatocytes, but it is not yet known in detail whether and to what extent this process is active in other cell types. In the present study, we found that treatment with protein translation inhibitors causes a significant increase in BMS-354825 CE-rich LDs. Translation inhibitors are frequently used in cell biological experiments, but the effect observed in the present study has not been given attention in the past. Earlier studies showed that treatment with cycloheximide suppresses autophagy. More recently, inhibition of protein synthesis was shown to activate mTORC1. We aimed to investigate whether the increase in CE-rich LDs that results from treatment with translation inhibitors was caused by mTORC1 activation and/ or suppression of autophagy. In the present study, we found that protein translation inhibitors cause a significant increase in CE-rich LDs. Because translation inhibitors are known to cause mTORC1 activation and autophagy suppression, we initially supposed that those processes were responsible for the increase in CE-rich LDs. Yet this increase in CE and LDs was observed even in the presence of mTORC1 inhibitors and in autophagy-deficient cells, indicating the engagement of other mechanisms. As a possible cause of the observed phenomena, we speculate that translation inhibitors may cause a down-regulation of CE hydrolysis: that is, CE hydrolytic enzymes may have a relatively short half-life and may decrease quickly when protein synthesis is suppressed. Hormone-sensitive lipase may be engaged in CE hydrolysis, but if its decrease were the main cause of the CE increase in CHX-treated cells, TG would be expected to increase simultaneously, and this was not observed in the present experiment. Other than HSL, several neutral CE hydrolases have been reported to be critical for CE digestion in macrophage foam cells, but their role in other cell types is not clear. Thus we are yet to examine the aforementioned possibility. We observed that the CHX-induced increase in CE and LDs also occurs in autophagy-deficient Atg5-null MEF, but this does not preclude the possibility that autophagy is involved in CE metabolism and LD turnover. In fact we found that significantly larger amounts of CE were observed in Atg5-deficient MEF than in wild-type MEF both before and after CHX treatment. Moreover, the PR-171 seemingly complete suppression of the autophagic flow in cells treated with CHX and Torin1 caused a significantly higher increase of CE than in cells treated with CHX alone, in which a low level of autophagy was occurring.

RAMs might determine a phenotypic drug-resistance without altering the secondary RNA-structure stability. Chronic myeloid leukemia is characterized by the constitutively activated tyrosine kinase BCR-ABL. Treatment of CML with the small molecule tyrosine kinase inhibitor imatinib stands as a paradigm for clinical efficacy of targeted small molecule therapy in malignant disease. Imatinib inhibits BCRABL tyrosine kinase activity and has been shown to effectively target the malignant clone in vitro and in vivo, resulting in a high percentage of long-term remissions in CML patients. Beyond CML, TKIs are currently either approved or evaluated in numerous other hematologic and solid neoplasms and may become cornerstones of novel treatment strategies in the near future.. Preclinical and clinical data derived from studies using imatinib and other compounds suggested that candidates for clinical development should exhibit a sufficiently long plasma half-life to facilitate persistent target inhibition: continuous exposure to imatinib concentrations $1 mM for at least 20 h is necessary to induce apoptosis in BCR-ABL transformed cells in vitro, and clinical trials demonstrated a close relationship between imatinib serum trough-levels and clinical response. Finally, the extent of BCR-ABL inhibition, as determined by the level of CRKL dephosphorylation, correlated with clinical activity. Therefore, it has been widely accepted that continuous and complete target inhibition is a prerequisite for clinical efficacy of TKI treatment. Recently, this paradigm has been challenged by data obtained in a clinical trial using the second generation BCR-ABL inhibitor dasatinib. Dasatinib demonstrated similar clinical activity but less side effects for once daily dosing with 100 mg as compared to twice daily dosing with 70 mg. Interestingly, the once daily dosing schedule apparently resulted in transient inhibition of BCR-ABL kinase activity only, as rephosphorylation of the BCR-ABL downstream adaptor protein CRKL was observed 8 h post dasatinib-dosing. In addition, in vitro and ex vivo studies suggested that high-dose pulse-exposure to TKI irreversibly commits BCR-ABL positive cells to apoptosis. This R428 effect was evident upon pulse treatment for only 20 min -4 h. It was proposed that depth, rather than duration of kinase inhibition, is the critical determinant for TKI efficacy. However, the molecular mechanism for apoptosis induction after HD-TKI pulse-exposure has remained elusive. In our present work, we demonstrate that KRX-0401 157716-52-4 dramatic intracellular drug retention mediates apoptotic cell death upon HD-TKI pulseexposure. In line with this, over-expression of ABC transporters prevented cell death upon HD-TKI pulse-exposure. These findings will be useful to rethink our current framework of pharmacokinetic requirements of TKIs for CML and other diseases. In addition, these studies refine the molecular concept of TKI-induced apoptosis. Induction of apoptosis upon HD-TKI pulse-exposure has been demonstrated by several groups. Based upon these findings, a concept of irreversible commitment to apoptosis upon HD-TKI pulse-exposure was proposed. However, the mechanism of induction of apoptosis upon HD-TKI pulse-exposure remained elusive at the molecular level. This prompted us to investigate the molecular mechanisms of cell death induced by HD-TKI pulse-exposure in more detail. It appeared unlikely that short-term potent kinase inhibition could initiate an irreversible cell death program without altering onset and kinetics of apoptosis. Indeed, the data presented here provide evidence that HD-TKI pulseexposure does not irreversibly initiate apoptosis, since cells can be completely rescued by drug wash-out.